|Bid||0.55 x 3200|
|Ask||0.57 x 4000|
|Day's Range||0.5200 - 0.5749|
|52 Week Range||0.3000 - 1.8400|
|Beta (3Y Monthly)||2.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Applied DNA Sciences Inc. (APDN) (“Applied DNA,” or “the Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, and TheraCann International Benchmark Corporation (“TheraCann”), a leading global full-service legal cannabis and hemp consultancy, announced today that they have entered into a non-binding Term Sheet (the “Term Sheet”) for a long term exclusive licensing agreement for the use of Applied DNA’s proprietary CertainT® supply chain integrity platform technology within TheraCann’s ETCH BioTrace® seed-to-sale tracking system. The Term Sheet is expected to be followed by a definitive agreement (the “Agreement”).
The Stony Brook, New York-based company said it had a loss of 11 cents per share. The DNA-based security technology company posted revenue of $884,300 in the period. Its adjusted revenue was $884,000. ...
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”), a leader in large-scale PCR-based DNA manufacturing, announced today that two prior announcements by Israel Cannabis raise the opportunity for uptake of Applied DNA’s CertainT® Cannabis Tagging platform within the Israeli cannabis industry. Central to the opportunity are agreements previously signed between Applied DNA and TheraCann International Benchmark Corporation (“TheraCann”), and between TheraCann and Israel Cannabis (“iCAN”). The agreement will allow iCAN to offer TheraCann’s (and hence, Applied DNA’s) technology to emerging markets in Europe, Africa and Asia, while allowing TheraCann clients access to iCAN’s technology pipeline and expertise.
Applied DNA Sciences, Inc. , announced today it plans to release financial results for its fiscal 2019 first quarter ended December 31, 2018 after market close on Thursday, February 7, 2019.
Applied DNA Sciences Inc. (APDN) (“Applied DNA,” “the Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the appointment of Stephen Birkhold to the Company’s Strategic Advisory Board (“SAB”) and retention as a consultant to assist the Company with market penetration in the fashion and luxury apparel and accessory markets. Mr. Birkhold is a 30-year veteran of the fashion industry and is the former CEO of several of the world’s most prominent apparel brands.
Tex-Ray’s Established Supply Chains, Geographic Reach and Technology Innovation to Position CertainT® to Offer Brand Protection and Traceability for Performance Fabrics, Smart Clot
Applied DNA Sciences, Inc. (APDN) (“Applied DNA,” “the Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the signing of a non-binding Memorandum of Understanding (“MOU”) with the Sun Chemical Supply Company of Taiwan (“Sun Chemical Supply”). Under the terms of the MOU, Sun Chemical Supply will serve as a distributor of the CertainT platform in the heart of Asia’s textiles industry. Established for over 60 years as a chemicals, synthetic materials and equipment distributor in China, Taiwan and Vietnam, Sun Chemical Supply will provide deep industry knowledge, infrastructure and client base to expand Applied DNA’s reach to service its currently commercialized business and further build its pipeline.
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the "Company"), a leader in large-scale PCR-based DNA manufacturing, announced today that on December 26, 2018 it closed its previously announced underwritten public offering (the “Offering”) of an aggregate of 5,500,000 shares of common stock, par value $0.001 per share (the “Common Stock”), together with warrants to purchase an aggregate of 5,500,000 shares of common stock (the “Warrants”) at an exercise price equal to $0.50 per share of Common Stock with Maxim Group LLC (“Maxim”), as the sole underwriter and book running manager. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are $2.75 million.
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the "Company"), a leader in large-scale PCR-based DNA manufacturing, announced today the pricing of an underwritten public offering of 5,500,000 shares of its common stock and warrants to purchase up to an aggregate of 5,500,000 shares of the Company’s common stock. Each share of common stock and each warrant to purchase one share of common stock is being sold at a combined effective price to the public of $0.50. Applied DNA has granted the underwriter an over-allotment option, exercisable for a period of 45 days, to purchase up to 825,000 additional shares of its common stock and/or 825,000 warrants to purchase common stock at the public offering price less discounts and commissions.
The Company intends to use the net proceeds from this offering for working capital, capital expenditures, business development and research and development expenditures. Maxim Group LLC is acting as sole underwriter and book-running manager for the offering. The securities described above are being offered under the Company’s shelf registration statement on Form S-3 (No. 333-218158), previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC).
The Stony Brook, New York-based company said it had a loss of 12 cents per share. The DNA-based security technology company posted revenue of $1.2 million in the period. For the year, the company reported ...
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the "Company"), a leader in large-scale PCR-based DNA manufacturing, announced selected preliminary unaudited financial results for the full fiscal year and quarter ended September 30, 2018. Revenues for fiscal 2018 totaled $3.9 million, a decrease of 18% from $4.8 million from the same period in the prior fiscal year. The decrease in revenues was attributable to a decrease in revenues of approximately $2.2 million in the textile industry for protecting cotton and synthetic supply chains. This decrease was offset by an increase in revenue from Contract Manufacturing of DNA for diagnostics as well as an increase from development projects, primarily those associated with partners’ pre-commercial business initiatives in legal cannabis and pharmaceuticals.
Applied DNA Sciences Inc. (APDN) (“Applied DNA,” “the Company”), a leader in large-scale PCR-based DNA manufacturing, announced today the signing of a Joint Development Agreement (the “Agreement”) with Everledger, Inc. (“Everledger”), an independent emerging technology enterprise. Under the Agreement the parties will develop and market a combined physical and digital supply chain traceability and certification solution utilizing the Company’s CertainT molecular tagging and authentication systems together with Everledger’s blockchain-based platform. The parties believe this joint solution platform is at the forefront of linking immutable digital transactions with synthetic molecular authentication to tightly track movement and chain of custody of forensically-identified goods across complex ecosystems.
Applied DNA Sciences, Inc. , the leader in large-scale PCR-based DNA manufacturing, today announced that Dr. James Hayward, president & CEO, will present at the Long Island Capital Alliance’s Cannabis Capital Forum in Melville, N.Y., on Friday, December 7 at 9:00 AM ET.
Management to Address the Potentially Critical Role of Its Platform in the Future of Gene Therapy, Vaccines and Adoptive Cell Therapies; Webinar Scheduled for December 6, 2018, 12:
If you want to know who really controls Applied DNA Sciences Inc (NASDAQ:APDN), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock Read More...
Applied DNA Sciences Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, is pleased to report that SigNature DNA evidence has resulted in over 131 convictions, with sentences of 625 years to date, and many more cases in the pipeline. The confirmed number of convictions and sentencing are received from law enforcement officers. The crimes we help solve with the aid of our SigNature DNA products include attacks against armored car companies, whose activity is commonly known across Europe as “Cash-and-Valuables-in-Transit.” Other types of crimes whose conviction benefits from Applied DNA’s technology include theft of entire vehicles and their components, Automated Teller Machine (ATM) burglary, and theft of goods from businesses and private residences.
MELVILLE, NY / ACCESSWIRE / November 21, 2018 / The Long Island Capital Alliance (''LICA''), Long Island's leading non-profit capital formation and business development organization, today announced the program for its Cannabis Capital Forum to be held on Friday, December 7, 2018, including the keynote speakers, presenting companies and investor and industry panelists.
Applied DNA Sciences Inc. (NASDAQ:APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the signing of a Collaboration Agreement (the “Agreement”) with Eurofins BLC Leather Technology Center LTD (“BLC”) to support the commercial implementation of Applied DNA’s SigNature® T-based leather traceability system (the “System”). Tony Benson, Applied DNA’s Managing Director with responsibility for Europe, Middle East and Africa (EMEA) commented, “We are thrilled to enter into this mutually beneficial relationship with BLC to advance the commercial implementation of our leather tagging system. Dr. James Hayward president and CEO of Applied DNA stated, “This agreement with BLC significantly enhances our position for the commercial implementation of our leather tagging system.
Applied DNA Sciences Inc. (APDN) (“Applied DNA”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx” or the “Company”) has been providing linear DNA to Technogenetics (Shanghai Kehua Bio-Engineering Co., Ltd-KHB group) that produces and sells kits to detect autoimmunity and infectious diseases. The purified, PCR-produced DNA is custom-made for Technogenetics and is used to prepare the basic component responsible for the diagnostic specificity of two kits: one kit is used for the determination of dsDNA autoantibodies and the other for an ANA (Anti-Nuclear Antibodies) Screen. “During the kits’ development, the Technogenetics R&D laboratories tested several polynucleotides.
Results of a new study published in the September/October 2018 issue of the AATCC Review confirmed that DNA molecular tagging is an effective tool to authenticate denim and maintains its integrity even after exposed to the rigors of bleaching and abrasion. The study was conducted by: Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), and the Fashion Institute of Technology (FIT). It was published in the AATCC Review, a highly regarded publication of the American Association of Textile Chemists and Colors.
Global manufacturer of home textiles GHCL, Limited (listed on NSE and BSE) launched CIRKULARITY™, a new brand of eight lines of bedding supporting the circular economy in September, at the New York home fashions market week. REKOOP®, the inspiration behind CIRKULARITY, is a brand of bedding products made from recycled plastic (rPET) and is the first bedding product to use the Applied DNA Sciences (“Applied DNA,” “the Company,” NASDAQ: APDN) CertainT® platform.